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ABSTRACT
Recent epitranscriptomics studies unravelled that
ribosomal RNA (rRNA) 2′O-methylation is an ad-
ditional layer of gene expression regulation high-
lighting the ribosome as a novel actor of transla-
tion control. However, this major finding lies on ev-
idences coming mainly, if not exclusively, from cel-
lular models. Using the innovative next-generation
RiboMeth-seq technology, we established the first
rRNA 2′O-methylation landscape in 195 primary hu-
man breast tumours. We uncovered the existence
of compulsory/stable sites, which show limited
inter-patient variability in their 2′O-methylation level,
which map on functionally important sites of the hu-
man ribosome structure and which are surrounded
by variable sites found from the second nucleotide
layers. Our data demonstrate that some positions
within the rRNA molecules can tolerate absence of
2′O-methylation in tumoral and healthy tissues. We
also reveal that rRNA 2′O-methylation exhibits intra-
and inter-patient variability in breast tumours. Its
level is indeed differentially associated with breast
cancer subtype and tumour grade. Altogether, our
rRNA 2′O-methylation profiling of a large-scale hu-
man sample collection provides the first compelling
evidence that ribosome variability occurs in humans
and suggests that rRNA 2′O-methylation might rep-
resent a relevant element of tumour biology useful in
clinic. This novel variability at molecular level offers
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an additional layer to capture the cancer heterogene-
ity and associates with specific features of tumour




Emerging evidence suggests that changes in ribosomal
RNA 2′O-ribose methylation (rRNA 2′OMe) in the hu-
man ribosome play a key role in regulating translation
thereby contributing in setting particular phenotypes such
as hallmarks of cancer cells (1–5). Using cancer cellular
models, we and others indeed reported an association be-
tween variation in rRNA 2′O-methylation and modulation
of translation efficiency of particular mRNA subsets in can-
cer (1,6–9). In particular, we demonstrated that inactiva-
tion of the tumour suppressor p53 protein in mammary ep-
ithelial cells is associated with an increased expression of
the 2′O-methyltransferase FBL, an alteration of the 2′O-
methylation level at some of the 106 rRNA-methylated sites
and an increased translation of some cellular Internal Ri-
bosome Entry Sites (IRES)-containing mRNAs such as
those encoding the oncogenic IGF1R and cMyc proteins
(1). Moreover, we have shown that FBL overexpression pro-
motes IGF1R-dependent proliferation, colony formation
and resistance to chemotherapy in breast cancer cell lines,
suggesting a role of rRNA 2′O-methylation in mammary
tumorigenesis and breast cancer progression (1). Impor-
tantly, using cell-free in vitro translation assays, we recently
demonstrated that modulation of rRNA 2′O-methylation
directly affects translation initiation of IRES-containing
mRNAs, the IGF1R mRNA and the Cricket paralysis virus
mRNA (2). This new layer of gene expression regulation re-
cently uncovered, joins the numerous descriptions of chem-
ical modifications of both coding and non-coding RNAs
that regulates post-transcriptional processes, a field known
as epitranscriptomics (3,4,10). However at present, it is un-
clear whether rRNA 2′O-methylation varies in humans.
Although genetics, genomics, epigenetics, transcrip-
tomics and proteomics revealed the heterogeneity of breast
tumours at the molecular level, identification of novel
molecular layers are required to fully capture all the inter-
patient variability, essential for developing clinical applica-
tions (11). Amongst them, epigenetics appears as promis-
ing additional molecular fingerprints to improve patient
classification, prognosis or treatment, including in breast
cancer (11–13). In these molecular portraits of breast can-
cers, RNA epitranscriptomics and more specifically rRNA
2′O-methylation, has never been investigated. Thanks to
the recent resolution of technological issues, including the
development of RNA-seq-based approaches dedicated to
the profiling of rRNA 2′O-methylation (4,5,14,15) and the
recent developments of high-resolution cryo-EM that has
provided insights into the detailed structure of the human
ribosome including rRNA modifications (16–18), rRNA
2′O-methylation profiling can now be achieved in human
samples to determine whether it can provide a molecular
fingerprint in breast cancer.
Here, we present the first rRNA 2′O-methylation land-
scape of human breast tumours. We used the next-
generation RiboMeth-seq technology that we remodelled to
perform high-throughput analyses of human clinical sam-
ples. Our data reveal the unexpected existence of specific
modulation of 2′O-methylation at only particular rRNA
positions between human breast tumours that are associ-
ated with clinical outcome and biological features.
MATERIALS AND METHODS
Human samples
A series of 195 female primary breast tumours were col-
lected from 1997 to 2011 and maintained by the Tayside Tis-
sue Bank (TTB, Dundee, Scotland, UK) under ethical ap-
proval (REC Reference 07/S1402/90) (Supplementary Ta-
ble ST1) (19). This retrospective series of primary breast
tumours is composed of both non-invasive (45%) and in-
vasive (55%) lymph node tumours (Supplementary Table
ST1). Total RNA was extracted from frozen tissues by TTB
services as already described (19,20). A second series of
7 mammoplasties (i.e. non-transformed, non-proliferative
but mostly adipocyte cells) derived from healthy donors was
sequenced independently (Institut Curie, France) (21). A
third series composed of 10 mammary malignant tumours
and 8 mammary benign tumours (i.e. non-transformed but
hyper-proliferative epithelial cells) were collected between
2006 and 2007 (Institut Gustave Roussy, France) from con-
senting patients using fine-needle aspiration after suspicion
of breast lesion (Supplementary Table ST2) (22). A human
RNA reference sample (i.e. RNA reference) was used as
a calibrated source of rRNA (Human XpressRef Univer-
sal Total RNA, Qiagen) prepared from 20 different human
adult and foetal normal major organs.
RiboMeth-seq
Levels of rRNA 2′O-methylation at the 106 rRNA
2′O-methylated sites were determined by RiboMeth-seq
(14,15,23–25). Presence of 2′O-methylation protects the
phosphodiester bond located at the 3′ of the 2′O-methylated
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2′O-methylation at the given nucleotide n induces under-
representation of RNA fragments starting at the nucleotide
n + 1 and ending at position n allowing to calculate a 2′O-
methylation level at the corresponding nucleotide position
(or C-score) varying from 0 to 1 (15). RiboMeth-seq was
performed using the Illumina sequencing technology and
raw data were processed as previously described (14,25).
The median number of total reads reaches 7.2 millions af-
ter trimming, these reads being aligned on the 7.2 kb-long
rRNA sequences, that corresponds to the optimal sequenc-
ing depth (14,26).
Analysis of the breast cancer series
Amongst an initial series of 214 primary breast tumours,
RiboMeth-seq data of 195 primary breast tumour sam-
ples passed the QC criteria (representing 91% of the initial
series) and were thus retained for the downstream analy-
ses (Supplementary Table ST1). Unsupervised data anal-
ysis was performed (hierarchical clustering and principal
component analysis (PCA)) using the C-scores at the 106
individual rRNA 2′O-methylated sites of the 195 samples.
rRNA 2′O-methylation profiles were shown as either box-
and-whiskers plots, line charts or barcharts. Classification
of the rRNA 2′O-methylation sites into ‘stable’ and ‘vari-
able’ classes was done empirically based on the variabil-
ity of the sites (in terms of interquartile range, IQR), the
cut-off site being the site from which the IQR values no
longer lie on this straight line (see Supplementary Ma-
terials and Methods for details). Between-group compar-
isons were performed using Fisher’s exact test for categori-
cal data or Mann–Whitney test for quantitative data. Bon-
ferroni or false discovery rate correction methods were ap-
plied for multiple comparisons (P.adj). All P-values cor-
responded to two-tailed P-values. A P-value < 0.05 was
considered to be statistically significant. Statistical analyses
and graphical representations were performed using either
R v3.6.3 or GraphPad Prism v7.0a software (GraphPad
Software, Inc).
rRNA 2′O-methylation evolution and mapping
To further characterize the two classes of human rRNA
2′O-methylated sites, their conservation during evolution
was compared using box C/D snoRNA guides as surro-
gates of rRNA 2′O-methylated sites, since to date availabil-
ity of rRNA 2′O-methylation profiles is limited to only few
organisms. Three evolution groups were established using
the snoRNA-LBME-db database (www-snorna.biotoul.
fr). Using Fisher’s exact test, enrichment analysis was per-
formed to compare the proportion of stable versus variable
sites amongst the three groups of rRNA 2′O-methylated
sites. The rRNA 2′O-methylated sites were mapped on the
structure of the HeLa cancer cell human ribosome deter-
mined by cryo-EM (16–18) and images were drawn using
the PyMol software. Observations were based on previous
reported three-dimensional molecular docking analysis of
tRNAs or ribosome-associated factors, as already discussed
in (ref 16–18).
RESULTS
Optimization of RiboMeth-seq technology for human sam-
ples
To profile rRNA 2′O-methylation in human primary breast
tumours, we used the novel RiboMeth-seq technology. The
measurement of 2′O-methylation frequency by RiboMeth-
seq technology relies on a partial alkaline hydrolysis of the
rRNA phosphodiester bonds, which become refractory to
hydrolysis when adjacent riboses are methylated in position
2′ (14,15,25). RiboMeth-seq processing yields a score (i.e.
C-score) at each of the 106 rRNA 2′O-methylated positions,
reflecting the level of 2′O-methylation.
Since rRNA 2′O-methylation profiling has never been
performed on large series of human samples, we devel-
oped RiboMeth-seq-dedicated extensive quality controls
based on numerous metrics (see Supplementary Materials
and Methods). Using human RNA reference samples com-
posed of a mix of 20 different human adult and foetal nor-
mal major organs and a test set of 20 primary breast tu-
mour samples, we show a strong correlation in the C-scores
amongst the technical replicates (Supplementary Figures
S1 and 2). Overall, our data demonstrate that the high-
throughput RiboMeth-seq technology is a reproducible and
robust technology even when sequencing delicate biological
material such as frozen tumour biopsies.
Identification of two classes of rRNA 2′O-methylation sites
We then profiled rRNA 2′O-methylation in a series of 195
primary breast cancers composed of a mix of invasive and
non-invasive tumours using RiboMeth-seq (Supplementary
Table S1) (20). Unsupervised statistical analysis revealed
variability in rRNA 2′O-methylation levels (Figure 1). It
first showed that, for a given tumour, the 2′O-methylation
level varies between 0 and 0.98 amongst the 106 rRNA
2′O-methylation sites (Figure 1 and Supplementary Fig-
ure S3a). This demonstrates that in a single human tumour
sample, all rRNA molecules are not fully and equally 2′O-
methylated at the 106 sites.
Hierarchical clustering also revealed that, for a given
rRNA site, 2′O-methylation levels differ when compar-
ing the 195 human tumours (i.e. inter-patient variabil-
ity) (Figure 1; Supplementary Figures S3a and 4). We de-
fined two classes of rRNA 2′O-methylated sites based on
the variability of their 2′O-methylation level amongst pa-
tients (Supplementary Figure S3c). The classification into
these two classes was done empirically based on the intra-
variability of the sites (in terms of interquartile range, IQR,
at a given site). The first class contains 60 rRNA 2′O-
methylated sites (56.6% of all the rRNA 2′O-methylated po-
sitions), the levels of which exhibit low inter-patient vari-
ability between the 195 tumour samples, despite these se-
ries representing the full spectrum of breast cancer sub-
types (Figure 2a and Supplementary Figure S4, red). There-
after, they are termed ‘stable’ sites since they display the
most stable C-scores between the 195 tumours. The sec-
ond class corresponds to a limited number of rRNA 2′O-
methylated sites (46 sites, around 43.4% of the rRNA 2′O-
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Figure 1. Stability and variability of rRNA 2′O-methylation levels between breast tumours. Levels of rRNA 2′O-methylation (i.e. C-score) were determined
at the 106 rRNA 2′O-methylated sites using RiboMeth-seq in a series of 195 primary human breast tumours. Data are presented as a hierarchical clustering
where the C-score of each position (column) for each tumour (row) is presented (colour scale). Dendrograms represent relationships of similarity between
breast tumours on the basis of their rRNA 2′O-methylation profiles (left panel) that identify four groups of breast tumour samples (right colour panel),
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Figure 2. Biological relevance of variable rRNA 2′O-methylation levels in breast cancer. (A) C-score variation amongst the 195 human primary breast
tumours at each of the 106 rRNA 2′O-methylated sites was ranked by increasing interquartile range (IQR). Based on IQR divergence, two classes of rRNA
2′O-methylated sites were defined: sites with the most stable C-scores (red); and sites with the most variable C-scores (blue). (B) Example of significant
change in rRNA 2′O-methylation levels at the 18S-Gm1447 site between luminal, HER2+ and TNBC breast tumours. (C) Summary of the four variable
rRNA sites, whose 2′O-methylation levels were significantly different between breast cancer subtypes, hormonal and HER2 receptors, and tumour grade.
ER: oestrogen receptor; PR: progesterone receptor; Luminal: ER+ PR± HER2−; HER2+: ER+/− PR+/− HER2+; TNBC: ER− PR− HER2-; G:
grade. (D) Comparison of rRNA 2′O-methylation profiles in a series of 8 benign (green) and 10 malignant (orange) tumours. An enlarged view presents the
significant change in rRNA 2′O-methylation levels at the variable 18S-Am576 site in malignant compared to benign mammary tumours, with carcinoma
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ability in their 2′O-methylation level (‘variable’ sites, blue).
Amongst them, the 28S-Am1313, 28S-Cm2352 and 28S-
Gm3723 sites displayed important inter-patient variability,
the C-scores ranging from 0 to >0.90 and a null C-score
being observed in different tumours (Figure 2a and Sup-
plementary Figure S3a). Position-by-position comparison
of the ∂C-score [(mean C-score + 2sd) – (mean C-score –
2sd)] between the 195 breast tumours and the statistical
analysis based on five technical replicates of normal hu-
man RNA reference samples reveals that the high inter-
patient variability in C-scores corresponds to a biological
variability rather than to technical variability (Supplemen-
tary Figure S3b). Similarly, these two classes of most sta-
ble and most variable sites derived from the 195 breast tu-
mours were observed in a series of 7 mammoplasties derived
from healthy female donors, most of the sites being classi-
fied in the same classes with the except of few ones (Supple-
mentary Figure S5). The difference might come either from
the small size of this series or from the fact that variabil-
ity in rRNA 2′O-methylation might be tissue-specific, mam-
moplasties mostly corresponding to adipocyte cells. These
data show that rRNA 2′O-methylation varies between hu-
man samples and demonstrate the co-existence of stable and
variable classes of rRNA 2′O-methylated sites within hu-
man samples.
Association of rRNA 2′O-methylation level with biological
and clinical characteristics
To assess the biological significance of the co-existence of
two classes of rRNA 2′O-methylated positions displaying
either the most ‘stable’ 2′O-methylation level between hu-
man tumour samples or the most ‘variable’ 2′O-methylation
level, we evaluated the association between variations in C-
score at the 106 rRNA 2′O-methylated positions and bio-
logical or clinical characteristics of primary breast tumours
(Figure 2B and C). Remarkably, amongst the stable rRNA
2′O-methylated sites, no association between change in C-
score and well-known characteristics of breast cancers was
observed (i.e. tumour grade, tumour size, lymph node in-
volvement, hormonal/HER2 receptor status, breast cancer
subtype or TP53 mutation). In contrast, we identified four
variable rRNA 2′O-methylated sites (18S-Gm1447, 28S-
Gm1303, 28S-Gm4588 and 18S-Am576), the levels of which
are significantly different between breast cancer subtypes,
oestrogen and progesterone statuses, as well as tumour
grades (Figure 2B and C; Supplementary Table S3). In both
human tumour samples and cell lines, the 2′O-methylation
level of the 18S-Gm1447 site decreased in triple-negative
breast cancers (TNBCs) compared to the luminal tumours,
whilst that of the 18S-Am576 site increased in TNBCs (Fig-
ure 2B and C; Supplementary Figure S6). Furthermore, we
compared rRNA 2′O-methylation profile in a small series
of eight benign (i.e. hyperproliferative, but non-transformed
epithelial cells) and 10 malignant tumours, the former do
not represent the full breast cancer inter-patient hetero-
geneity. In this series, 2′O-methylation level at the 18S-
Am576 site distinguished benign from malignant mammary
tumours (Figure 2D).
Secondly, we evaluated the association between breast
cancer patients harbouring tumours exhibiting similar
rRNA 2′O-methylation profiles and biological/clinical
characteristics of breast tumours. Hierarchical clustering
and PCA methods identified 4 clusters of breast cancer tu-
mours based on their rRNA 2′O-methylation profiles (Fig-
ures 1 and 3A). Analysis of survival indicates that, although
no significant association was observed, the patients car-
rying breast tumours characterized by distinct rRNA 2′O-
methylation profile display distinguishable overall survival
(Figure 3B). In particular the ‘blue’ group displays the poor-
est overall survival. This blue group was enriched in TNBC
and in tumours of high grade compared with the other
groups (Figure 3C and D; Supplementary Figure S7). Re-
garding the fact that tumours in the blue groups exhibited
the lowest C-score at most of the rRNA 2′O-methylated
sites (Figure 1), these data suggest that global decrease in
rRNA 2′O-methylation might be associated with breast tu-
mour aggressiveness. Finally, clustering breast cancer tu-
mours on the basis of their 2′O-methylation level at the 106
rRNA sites highlights at diagnosis, patients carrying small
tumours size who display prognosis as poor as patients car-
rying large tumours size (Figure 3E, blue group). Indeed,
patients carrying small tumour size exhibit different sur-
vival rates depending on the rRNA 2′O-methylation profile.
Overall, these data indicate that 2′O-methylation levels at
variable rRNA sites are associated with breast cancer sub-
types and tumour grade.
Evaluation of the structural impact of the two classes of
rRNA 2′O-methylation sites
To further characterize the two classes of human rRNA
2′O-methylated positions identified in the 195 breast tu-
mours, we compared their conservation during evolution.
Amongst the 106 rRNA 2′O-methylation sites described
in humans, some sites have also been identified in yeast
and bacteria (snoRNA-LBME-db database, www-snorna.
biotoul.fr). We thus compared the proportion of either ‘sta-
ble’ or ‘variable’ sites classified on the basis of our data,
amongst three groups: the group of rRNA 2′O-methylated
sites only detected in humans (‘humans’, n = 68); the group
of rRNA 2′O-methylated sites detected both in humans and
yeast (‘eukaryotes’, n = 35); and the group of rRNA 2′O-
methylated sites conserved in humans, yeast and bacteria
(‘universal’, n = 3; see also annotation on the human ribo-
some structure in ref 17). Enrichment analysis showed an
increased proportion of the variable rRNA 2′O-methylated
sites in humans compared to other organisms (Figure 4A),
suggesting a link between the appearance of variable rRNA
2′O-methylated sites and evolution, characterized by an
increasing number of fine-tuning gene expression mecha-
nisms.
We then mapped the stable and variable rRNA 2′O-
methylated positions on the human ribosome structure (16–
18). It revealed an interesting distribution in space, where
the decoding centre (DC), the peptidyl-transferase centre
(PTC) and the polypeptide exit tunnel are mostly decorated
with stable 2′O-methylated positions, whilst some variable
positions are found in 1 or 2 nt layers away from the func-
tional sites (i.e. maximum 4.5 Å away from the functional
sites) (Figure 4B and C, annotated sites). However, 2′O-
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Figure 3. Association of rRNA 2′O-methylation profiles with biological and clinical breast cancer characteristics. (A) PCA showed four clusters of breast
tumours based on their rRNA 2′O-methylation profiles that correspond to the ones identified using the hierarchical clustering approach (Figure 1). (B)
Kaplan–Meier curve suggested the patients carrying breast tumours characterized by a ‘blue’ rRNA 2′O-methylation profile display the poorest overall
survival. (C and D) Significant differences in repartition amongst the four clusters were observed regarding tumour grade (C) and breast cancer subtype
(D). Luminal: ER+ PR± HER2−; HER2+: ER+/− PR+/− HER2+; TNBC: ER− PR− HER2−. (E) Kaplan–Meier curve depicts the overall survival






/narcancer/article/2/4/zcaa036/6042944 by guest on 24 February 2021
8 NAR Cancer, 2020, Vol. 2, No. 4
Figure 4. Structural properties of stable and variable rRNA 2′O-methylated sites. (A) Amongst the 106 rRNA 2′O-methylated sites in humans, 68 are
specific to humans (humans), 35 are found across eukaryotes (eukaryotes) and 3 are conserved from bacteria to humans (universal) (left panel). The
proportion of stable and variable sites amongst these three groups is represented using pie charts (right panel). (B and C), Mapping of the two classes of
rRNA 2′O-methylated sites on the human ribosome (B) and at the PTC (C). Only rRNA 2′O-methylated positions directly involved in function domains or
in interaction with components of the translational machinery have been annotated. (D–F) Structural environment of the variable rRNA 2′O-methylated
sites significantly associated with breast cancer features. Red: stable sites; blue: variable sites; dotted circles: rRNA 2′O-methylation sites of interest; DC:
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carbon in very few 2′O-methylated sites are directly involved
in van der Waals contacts with tRNAs, mRNA and other
ribosome functional large ligands, as can be predicted from
modelling these into the human ribosome structure. Most
tRNAs binding regions in the large and small subunits are
decorated with stable 2′O-methylated positions with the
exception of 4 variable 2′O-methylated sites (18S-Um627,
28S-Am3739, 28S-Gm4340 and 28S-Cm4426) (Figure 4B).
In particular, the 28S-Am3739 nucleotide is located at the
hairpin loop of helix H69, which is located right next to
the inter-subunit rotation centre describing pre- and post-
translocation rotational states of the 40S with respect to
the 60S ribosomal subunit and whose 2′O-methylation may
influence P-site tRNA binding. The variable 28S-Gm4340
site is located at the CCA end region of the E-site tRNA
that provides favourable van der Waals contacts to the E-
site tRNA as observed experimentally in the human 80S
structure. Finally, the four rRNA sites displaying changes
in 2′O-methylation associated with biological and clinical
features of breast cancer (28S-Gm1303, 18S-Gm1447, 28S-
Gm4588 and 18S-Am576), are located at the periphery of
the PTC of the ribosomes and are accessible for tRNAs,
mRNA and other ribosome functional large ligands such
as GTPases that associate transiently during the transla-
tion process (Figure 4C–F). Various factor binding pockets
and their vicinity are mostly decorated with variable sites.
Molecular docking tRNA and ribosomal factors suggest
that stable rRNA 2′O-methylated sites are mostly located at
the catalytic sites of the ribosomes, whilst the variable sites
are found at the regulatory sites of the ribosomes.
DISCUSSION
Taken together, we show here for the first time that rRNA
molecules exist naturally in humans as molecules not fully
and equally 2′O-methylated at all the 106 positions. Indeed,
our structure/function and evolution enrichment analyses
as well as the differential association with biological char-
acteristics, demonstrates that at least two classes of rRNA
2′O-methylated sites concur in human breast cancers, de-
pending on their ability to tolerate (i.e. variable sites) or
not (i.e. stable sites) the absence of chemical modifications.
This unique discovery made by comparing human samples
demonstrates the co-existence of stable and variable 2′O-
methylation at specific rRNA positions.
Historically, plethora of studies mainly performed in
both yeast and Xenopus laevis models, which have been the
historical prototypic, eukaryotic models used during many
years finely decipher the highly complex molecular mecha-
nisms of rRNA transcription, chemical modifications and
processing (27–31). These studies allowed the mapping of
rRNA 2′O-methylation sites but also the demonstration of
the importance of 2′O-methylation in the conserved intrin-
sic activity of the ribosome, on which life relies. Indeed, it
appeared over the past years that loss of 2′O-methylation
at a few number of rRNA sites in yeast is critical for ri-
bosome functions and induces cell death (27,32). However,
more recent findings indicate that in yeast, loss of rRNA
2′O-methylation at other sites have only little or no effect.
Our finding sustain the emerging notion that rRNA
chemical modifications provide plasticity to the ribosome
structure on which its regulatory effects rely, thus extending
the modulation and activity of the ribosome to translational
regulation in humans, including in cancer (4,33). In a sin-
gle human sample, it appears that rRNA 2′O-methylation
varies between the 106 rRNA 2′O-methylated positions (0
< C-score < 0.98). It indicates that even within a single hu-
man sample, rRNA molecules exist naturally as molecules
not fully and equally 2′O-methylated at all the 106 posi-
tions. This observation is consistent with previous stud-
ies that were performed, albeit in limited number of mod-
els, either in cell lines (i.e. HeLa, PA1, HCT-116 and 293)
(2,8,18,34–37), in cellular models describing tumour ini-
tiation and progression of solid and haematological can-
cers (1,6,38) or in few number of adult/embryonic organs
(39). In addition to these previous studies, our findings also
demonstrate that difference in rRNA 2′O-methylation oc-
cur between different human samples and reflects inter-
patient variability. Variation in rRNA 2′O-methylation level
between tumours might result from different mechanisms.
Change in 2′O-methylation levels can result from alter-
ation in expression of each individual component of the
rRNA 2′O-methylation complex (i.e. the rRNA methyl-
transferase FBL, the structural proteins Nop56, Nop58 or
NHP2L1, or the small nucleolar snoRNA, which hybridizes
in a sequence-specific manner the rRNA and thus specifi-
cally guides the enzyme) (1,7,9,28). Expression of these dif-
ferent components has been correlated with genomic al-
teration, loss of tumour suppressor or oncogene activation
(1,7,28,40), suggesting that the 106 rRNA 2′O-methylation
sites can reflect numerous alterations of the tumour. More-
over, changes in the ratio substrate:enzyme (rRNA:rRNA
2′O-methylation complex) might be sufficient to alter rRNA
2′O-methylation level, the rRNA level being also dependent
of particular tumour suppressors and oncogenes (41). Inter-
estingly, the rRNA 2′O-methylated positions that are not
fully 2′O-methylated in a single human sample overlap with
those displaying strong inter-variability between breast can-
cer samples. Development of statistical and methodologi-
cal tools for future meta-analyses will be required to iden-
tify the complete list of rRNA sites accepting lack of 2′O-
methylation, either commonly or specifically to a particular
physio/pathological context.
The diversity of rRNA 2′O-methylation profiles naturally
occurring in humans reinforces the altered translational
control induced by experimental modulation of rRNA 2′O-
methylation (1,2,28). Amongst the variable rRNA 2′O-
methylation positions, the 18S-Gm1447 displays the high-
est variability in rRNA 2′O-methylation amongst tumours
with the identification of human tumours and breast can-
cer cell lines that lack 2′O-methylation at this particular nu-
cleotide. 18S-Gm1447 is in close vicinity of the uS10 riboso-
mal protein, which has been shown to bind to HCV IRES,
regulates translation initiation of short 5′UTR containing
mRNAs and contributes in resolving stalled ribosomes (42–
46). Thus, absence or presence of rRNA 2′O-methylation at
18S-Gm1447 might finely modulate uS10 activity, which ap-
plies to the intrinsic ribosome function in general depending
on its plasticity. Overall, our data reinforce, in humans, both
the existence of rRNA 2′O-methylated compulsory/stable
sites, which display no or low inter-patient variability and
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structural observations, and of rRNA 2′O-methylated plas-
tic sites, which provides novel properties to the ribosome
that can now be seen as a direct actor of translational regu-
lation.
In addition to 2′O-methylation, rRNA exhibits other
chemical modifications that affect translational regula-
tion and contribute in the acquisition of cancer hall-
marks. rRNA pseudouridylation () remains the proto-
typic example. Alteration in  rRNA profile induced by
mutant DKC1, the enzyme-directed rRNA pseudouridine
synthesis, has been shown to inhibit translation of the
tumour suppressor p53 protein (47,48). More recently,
the 18S-U609/U863 has been shown to display tumour
suppressive activity in response to KRAS-induced onco-
genic stress in liver cancer (49). Similarly, loss of 18S-
m1acp3U1248 and 28S-m6A4220 rRNA are associated
with colorectal and hepatocellular carcinoma, respectively
(50,51). Thus, like other rRNA chemical modifications,
rRNA 2′O-methylation can regulate translation and might
provide novel molecular understanding of cancer biology,
as it has been previously suggested, alteration of rRNA
2′O-methylation profile impairing cell proliferation and re-
sistance to chemotherapy (1). Future studies will thus be
required to finely identify rRNA 2′O-methylation sites in-
volved in tumorigenesis by comparing series of normal and
tumour breast tissues. Here, using benign tissue correspond-
ing to non-transformed epithelial, we identify that in hyper-
proliferative cells 2′O-methylation level of the 18S-Am576
site differs between benign and malignant tumours, sug-
gesting that the rRNA 2′O-methylation profile is different
between transformed and non-transformed tissue. It has to
be noted that due to the cycling evolution of breast cancer
through life (i.e. menstruation, pregnancy, menopause. . . )
and the discrepancies between benign tumours (i.e. hyper-
proliferative), mammoplasty (i.e. astrocyte enrichment) or
stromal tissue (i.e. molecular traits) and breast cancer tis-
sues (52), it remains difficult to build matched collection of
normal mammary tissues.
Our data also demonstrate that rRNA 2′O-methylation
corresponds to an additional layer of molecular character-
ization of breast cancer patient heterogeneity. Indeed, we
show for the first time that rRNA 2′O-methylation levels
differ between breast cancer subtypes and tumour grades.
rRNA 2′O-methylation corresponds to an additional layer
of molecular characterization that may help in the near fu-
ture to improve breast cancer patient classification but also
patients management. First, rRNA 2′O-methylation might
be useful to improve the refinement of breast cancer patients
stratification required in precision medicine. For example,
the rRNA 2′O-methylation profile could help in identify-
ing patients with the poorest outcome although they carry
small tumours that are generally associated with a low risk
factor in breast cancer. Such patients may thus benefit from
a more aggressive treatment protocol usually reserved to
treat largest breast tumours. Second, cancer-specific alter-
ations of ribosome structure induced by naturally occurring
variation in rRNA 2′O-methylation might be the source
of powerful and specific anti-cancer molecules (18,53). In-
deed, presence or absence of 2′O-methylation at a partic-
ular position might provide formation of specific ligand
pockets to specifically target cancer-related ribosomes. In
cancer, ribosome indeed appears as an emerging therapeu-
tic target, inhibitors of RNA polymerase I activity specifi-
cally killing cancer cells being currently evaluated in clinical
trials (54) and small molecules such as eukaryote-specific
antibiotics directly targeting the human ribosome reduc-
ing proliferation of cancer cells (18,53,55–57). However, fu-
ture studies will be required to determine whether diver-
sity in rRNA 2′O-methylation profiles result from the intra-
tumoral heterogeneity and/or heterogeneity in chemically
modified rRNA molecules between and/or within a single
cell.
The discovery of rRNA chemical modifications promot-
ing ribosome plasticity will undoubtedly lead to a deeper
and more complete understanding of rRNA chemical mod-
ifications in ribosome function and of cell fate determina-
tion providing a novel layer of cancer-related molecular fin-
gerprinting.
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